Publications by authors named "J Weclawek-Tompol"
Article Synopsis
- Choriocarcinoma in neonates and infants (N-CC) is a rare but aggressive cancer often linked with maternal disease, with a median patient age of 6 weeks.
- A study analyzing eight cases revealed that all tumors were diffuse, and most patients underwent a platinum-based treatment regimen, with some requiring surgery for residual tumors.
- Despite a poor overall outcome, including half of the patients dying from the disease, four patients achieved complete remission, highlighting the potential for successful treatment through multimodal therapy.
Background/aim: The role of immune checkpoint inhibitors (ICIs; anti-PD1) in the treatment of childhood cancers is still evolving. The aim of this nationwide retrospective study was to assess the safety and effectiveness of ICIs used in a group of 42 patients, with a median age of 13.6 years, with various types of advanced malignancies treated in pediatric oncology centers in Poland between 2015 and 2023.
View Article and Find Full Text PDFArticle Synopsis
- The study analyzes the effects of different radiotherapy (RT) techniques on patients with localized rhabdomyosarcoma (RMS), focusing on prognosis based on treatment variations.
- Among 1,470 patients followed over an average of 6.5 years, irradiated patients showed improved event-free survival (EFS) and local control survival (LCS) compared to nonirradiated patients, particularly in IRS II and III risk groups.
- The findings suggest that RT can be avoided for patients with IRS I embryonal RMS, while its use significantly benefits those in higher risk groups, with various doses showing similar efficacy across favorable and unfavorable risk profiles.
Pediatric Patients with Stage IV Rhabdomyosarcoma Significantly Benefit from Long-Term Maintenance Therapy: Results of the CWS-IV 2002 and the CWS DOK IV 2004-Trials.
Cancers (Basel)
March 2023
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma (STS) in childhood. Whereas more than 90% of patients with localized low-risk RMS can be cured, metastatic RMS have a dismal outcome, with survival rates of less than 30%. The HD CWS-96 trial showed an improved outcome for patients receiving maintenance therapy after completing intensive chemotherapy.
View Article and Find Full Text PDFIntroduction: Myeloid sarcoma (MS) is an extramedullary malignant tumor composed of immature myeloid cells. It occurs in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myeloid leukemia (CML). MS may coincide with disease diagnosis or precede bone marrow involvement by months or even years; it can also represent the extramedullary manifestation of a relapse (1, 2).
View Article and Find Full Text PDF